Phaseline

Targets › NPM1

NPM1 (Nucleophosmin): drug programs, companies and trials

4 programs from 4 companies in 18 trials: 9 Phase 2, 5 Phase 1, 2 Phase 3, 2 Phase 4; Oncology; next expected readout Jan 2027.

Involved in diverse cellular processes such as ribosome biogenesis, centrosome duplication, protein chaperoning, histone assembly, cell proliferation, and regulation of tumor suppressors p53/TP53 and ARF. Binds ribosome presumably to drive ribosome nuclear export. Associated with nucleolar ribonucleoprotein structures and bind single-stranded nucleic acids. (UniProt, P06748)

Open in Phaseline: the race on NPM1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisCeritinib (LDK378)
ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor
ALK, EML4, NPM1Phase 4ALK Positive Malignancies; ALK-positive NSCLC; Neuroblastoma; ALK Positive …Apr 2027
Pfizercrizotinib
Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
MET, ALK, EML4, NPM1, ROS1Phase 4NSCLCMar 2028
IDEAYA BiosciencesCrizotinib
Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
MET, ALK, EML4, NPM1, ROS1Phase 3Uveal Melanoma; Metastatic Uveal Melanoma; ALK Gene Rearrangement; Advanced Lymphoma …Jan 2027
Miltenyi BiomedicineMB-dNPM1-TCR.1
T cell receptor (TCR) therapy targeting dNPM1 peptide epitopes restricted to HLA A*02:01
NPM1Phase 1Leukemia, Myeloid, AcuteJun 2028

Conditions

Advanced Lymphoma (4) Non-small Cell Lung Cancer (2) Uveal Melanoma (1) Metastatic Uveal Melanoma (1) ALK Gene Rearrangement (1) Lung Cancer Stage III (1) Metastatic Colorectal Cancer (1) Advanced Malignant Solid Neoplasm (1) ALK Positive Malignancies (1) ALK-positive NSCLC (1) Neuroblastoma (1) ALK Positive (1)

Modalities

small molecule (2), mixed (1), protein or peptide (1)

Companies

IDEAYA Biosciences (1) Novartis (1) Pfizer (1) Miltenyi Biomedicine (1)

Related targets

ALK (3) EML4 (3) MET (2) ROS1 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.